Yunkang Group Limited
2325.HK
Hong Kong Stock Exchange0.65
HKD
- -
- -
Yunkang Group Limited
2325.HK
(Hong Kong Stock Exchange)
Recent
price
0.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Yunkang Group Limited (2325.HK) is an investment holding company that operates as a medical operation service provider in the People's Republic of China, primarily engaged in diagnostic testing services through independent clinical laboratories and on-site diagnostic centers. The company offers three core business lines: diagnostic testing services for medical institution alliances, which assist hospitals in establishing or upgrading on-site diagnostic centers in areas such as infectious diseases, reproductive health, genetic diseases, and pathology, including testing technologies, professional technicians, standard operating procedures, diagnostic consultation, staff training, equipment procurement, smart IoT, and logistics assistance; diagnostic outsourcing services to hospitals, other medical institutions, and public health institutions, encompassing pathology tests, infectious disease diagnostic tests, and genetic reproduction and screening tests; and diagnostic testing services for non-medical institutions, such as personalized diagnostic testing, medical report consultation, and hospital referral services for financial institutions and insurance companies. Founded in 2008 and headquartered in Guangzhou, the company conducts operations across mainland China, with independent laboratories in key cities including Guangzhou, Chengdu, Shanghai, Hefei, Kunming, and Nanchang, offering approximately 3,800 testing items and processing over 10 million specimens annually as of December 31, 2024; it holds the largest number of ISO15189 and CAP dual-certified independent clinical labs in China and serves as the sole China branch of the Clinical and Laboratory Standards Institute (CLSI). Recent developments include strategic collaborations with the People's Government of Ouhai, Wenzhou City, and Wenzhou Medical University to build biomedical projects like joint innovation platforms, public service platforms, medical big data centers, regional diagnostic sharing centers, and talent training bases; partnerships with Zhangjiang Research Institute of Fudan University for a Collaborative Innovation and Transformation Center in medical diagnostics; and alliances with Central University of Finance and Economics' Greater Bay Area Research Institute for industry-education fusion and incubation platforms, alongside increased R&D investment to RMB53 million in 2024 (7.4% of revenue) focused on AI digitalization, product innovation, and clinical applications amid revenue optimization and asset impairment provisions.